Skip to main content
. 2023 Jun 13;129(3):416–425. doi: 10.1038/s41416-023-02306-x

Table 3.

HRs and 95% CIs for the association categories of cumulative average intake of total olive oil and breast cancer tumor subtypes in the NHS and NHSII.

Never or <1 per month >0– ≤ 4.5 g/d ( >0 to ≤1 teaspoon) >4.5– ≤7 g/d ( >1 teaspoon to ≤1/2 TBS) >7 g/d ( >1/2 TBS) P- trend
ER-negative breast cancer (case n = 1416)
N° cases/ Person-years 386/1100933 759/1934091 127/313200 144/403532
Age-adjusted model 1 (Ref.) 1.16 (1.02, 1.32) 1.19 (0.97, 1.46) 1.03 (0.84, 1.25) 0.80
Multivariable model 1 (Ref.) 1.13 (0.98, 1.28) 1.16 (0.93, 1.44) 1.01 (0.81, 1.25) 0.69
ER-positive breast cancer (case n = 6860)
N° cases/ Person-years 1,646/1099737 3,638/1931419 679/312702 897/402820
Age-adjusted model 1 (Ref.) 1.13 (1.06, 1.20) 1.22 (1.11, 1.33) 1.19 (1.09, 1.30) <0.01
Multivariable model 1 (Ref.) 1.03 (0.97, 1.10) 1.07 (0.97, 1.18) 1.03 (0.93, 1.13) 0.71
p-heterogeneitya = 0.99
Luminal A breast cancer (case n = 2668)
N° cases/ Person-years 765/972970 1,361/1336018 248/194625 294/236045
Age-adjusted model 1 (Ref.) 1.07 (0.97, 1.17) 1.19 (1.03, 1.38) 1.10 (0.95, 1.26) 0.13
Multivariable model 1 (Ref.) 1.00 (0.91, 1.10) 1.08 (0.92, 1.26) 0.97 (0.83, 1.12) 0.88
Luminal B breast cancer (case n = 1220)
N° cases/ Person-years 305/973399 654/1336630 116/194737 145/236181
Age-adjusted model 1 (Ref.) 1.21 (1.05, 1.39) 1.30 (1.04, 1.61) 1.24 (1.01, 1.51) 0.11
Multivariable model 1 (Ref.) 1.14 (0.99, 1.32) 1.22 (0.97, 1.53) 1.15 (0.92, 1.44) 0.38
HER2-enrichedb (case n = 226)
N° cases/ Person-years 58/973632 127/1337102 23/194816 18/236290
Age-adjusted model 1 (Ref.) 1.28 (0.93, 1.76) 1.42 (0.87, 2.33) 0.86 (0.50, 1.48) 0.53
Multivariable model 1 (Ref.) 1.17 (0.84, 1.62) 1.27 (0.76, 2.13) 0.77 (0.43, 1.37) 0.33
Basal-like tumorsb (case n = 260)
N° cases/ Person-years 100/973596 121/1337109 18/194823 21/236288
Age-adjusted model 1 (Ref.) 0.99 (0.75, 1.30) 1.02 (0.61, 1.70) 1.00 (0.62, 1.62) 0.96
Multivariable model 1 (Ref.) 1.01 (0.76, 1.33) 1.05 (0.62, 1.78) 1.03 (0.61, 1.72) 0.88
p-heterogeneitya = 0.54

Results are expressed as Hazard Ratios (HR) and 95% Confidence Intervals (95% CI).

Multivariable model: adjusted for ethnicity (white, non-white), Southern European/Mediterranean ancestry (yes, no), age at menarche ( <12, 12, 13, 14, >14 years), menopausal status and age at menopause (premenopausal, <45, 45–49, 50–52, 53 + , unknown), postmenopausal hormone use (never user, past user, current user– estrogen only for <5 years, current user – estrogen only for ≥5 years, current estrogen + progestin user for <5 years, current estrogen + progestin user for ≥5 years, current user of other types), oral contraceptive use history (never, ever), parity and age at first birth (nulliparous, 1 child before age 25, 1 child at ≥25 years of age, 2+ children before age 25, 2+ children ≥25 years of age), breastfeeding history (never, breastfed for ≤ 6 months, breastfed for > 6 months), family history of breast cancer (yes or no), history of biopsy-confirmed benign breast disease (yes or no), height ( <1.60, 1.60–1.64, 1.65–1.69, 1.70–1.74, 1.75 + m), cumulatively updated total caloric intake (kcal/day, quintiles), physical activity (continuous MET-hours/week), neighborhood-based socioeconomic status indicator (continuous), BMI at age 18 ( <20.0, 20.0–21.9, 22.0–23.9, 24.0–26.9, ≥27.0) and AHEI-2010 (without alcohol and polyunsaturated fatty acids components, quintiles).

NHS Nurses’ Health Study, NHSII Nurses’ Health Study II.

aFor testing heterogeneity by subtype, we used the Lunn–McNeil approach, for multivariable model 1.

bDue to smaller sample sizes in analyses, to ensure that models would run, covariate categorizations were simplified.